By Ed Coghlan
As the American Headache Society (AHS) annual meeting takes place this weekend in San Diego, a lot of attention will justifiably be focused on a new class of drugs to treat migraines.
The drugs, known as calcitonin gene-related peptide (CGRP) monoclonal antibodies are being developed by four pharmaceutical companies: Alder Pharmaceuticals, Amgen, Eli Lilly and Company, and Teva Pharmaceuticals. Their work is being described as a transformative moment in migraine treatment,” by Peter Goadsby, MD, PhD, chair of the scientific program of the AHS annual Scientific Meeting.
Dr. Goadsby was interviewed by the National Pain Report this week in advance of the AHS meeting and he was stressing the need for more research into migraines. (click here)
Beyond the excitement over the CGRP research and study data, there are a number of other topics that will be reviewed. Three main areas will be highlighted at the meeting as a number of scientific papers and sessions have been schedule for presentation and discussion: the biology of migraines and headaches, the impact that they have and migraine treatment.
Some of the important topics that have been researched and will be discussed this wekend include:
- Posttraumatic headaches persist five years after traumatic brain injury
Headache is the most frequently reported symptom following a traumatic brain injury, it can continue to impact patients five years after the injury occurred.
- Women with Obesity are undertreated for Migraine Pain
On average 43% of headaches in women with migraine and obesity go untreated, contradicting the common misconception that migraine sufferers overuse medications.
- Individual Mapping of Migraine “Triggers & Protectors” May Give Personal Relief to Patients
Increasing an individual’s knowledge about their potential migraine triggers, protectors and associated behaviors may enable them to improve their condition.
- Migraine Stigma Prevents Proper Diagnosis and Treatment in Men
While migraine is the most common neurological disorder in both men and women, the stigma that migraine is a women’s disease can cause men to be under diagnosed and under treated.
- Migraine and Inflammation Linked to Young Adults
A common marker of inflammation and cardiovascular and stroke risk is elevated in the blood of young adults with migraine.
According to the Migraine Research Foundation, amazingly, 12% of the population – including children – suffers from migraine. It is found more often in women than men, 18% of American women, 6% of men, and 10% of children experience migraines.
The American Headache Society (AHS) is a professional society of health care providers dedicated to the study and treatment of headache and face pain. The meeting has attracted physicians, nurses and other health care providers to hear about progress that is being made in the battle against headaches and facial pain.